Not So Much of a Change | GenomeWeb

Matthew Herper at Forbes argues that the biotech boom of the past two years has been spurred by new drug launches and research breakthroughs. However, he cautions that some investors are currently "seeing rainbows and missing the rain."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Tech of the Future

And, Poof, It's Gone

Extra Hurdles

Down the Road a Ways

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.